Compare Stocks: ME, MNOV, HRTX, and DWTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$1.93 +4.6%	$1.55	$1.28 ▼ $9.50	$61.88M	1.71	46,917 shs	56,015 shs
HRTX Heron Therapeutics	$0.34 +5.3%	$0.44	$0.30 ▼ $1.58	$61.29M	1.65	2.71 million shs	3.58 million shs
ME 23andMe	$0.61	$0.50	$0.53 ▼ $9.57	$16.27M	1.19	1.57 million shs	N/A
MNOV MediciNova	$1.33 +0.8%	$1.34	$1.17 ▼ $1.96	$64.97M	0.63	38,033 shs	13,117 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	+4.62%	+5.19%	+39.49%	-2.78%	-60.31%
HRTX Heron Therapeutics	+5.28%	-32.47%	-18.23%	-62.64%	-73.98%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	+21.75%
MNOV MediciNova	+0.76%	0.00%	-2.21%	-5.00%	+2.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$1.93 +4.6%	$1.55	$1.28 ▼ $9.50	$61.88M	1.71	46,917 shs	56,015 shs
HRTX Heron Therapeutics	$0.34 +5.3%	$0.44	$0.30 ▼ $1.58	$61.29M	1.65	2.71 million shs	3.58 million shs
ME 23andMe	$0.61	$0.50	$0.53 ▼ $9.57	$16.27M	1.19	1.57 million shs	N/A
MNOV MediciNova	$1.33 +0.8%	$1.34	$1.17 ▼ $1.96	$64.97M	0.63	38,033 shs	13,117 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	+4.62%	+5.19%	+39.49%	-2.78%	-60.31%
HRTX Heron Therapeutics	+5.28%	-32.47%	-18.23%	-62.64%	-73.98%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	+21.75%
MNOV MediciNova	+0.76%	0.00%	-2.21%	-5.00%	+2.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DWTX Dogwood Therapeutics	2.00	Hold	$12.00	523.38% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	486.68% Upside
ME 23andMe	0.00	N/A	N/A	N/A
MNOV MediciNova	2.67	Moderate Buy	$8.33	526.57% Upside

Current Analyst Ratings Breakdown

Latest ME, MNOV, HRTX, and DWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/24/2026	DWTX Dogwood Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/3/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$2.00
6/2/2026	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/19/2026	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
HRTX Heron Therapeutics	$154.90M	0.42	N/A	N/A	$0.07 per share	4.87
ME 23andMe	$208.78M	0.08	$0.65 per share	0.93	$2.34 per share	0.26
MNOV MediciNova	$410K	159.66	N/A	N/A	$0.85 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DWTX Dogwood Therapeutics	-$34.26M	-$10.60	N/A	N/A	N/A	N/A	-108.57%	-30.28%	8/12/2026 (Estimated)
HRTX Heron Therapeutics	-$20.19M	-$0.18	N/A	N/A	N/A	-22.52%	-265.11%	-10.02%	N/A
ME 23andMe	-$666.70M	-$15.45	N/A	N/A	N/A	-183.39%	-170.07%	-62.13%	N/A
MNOV MediciNova	-$12M	-$0.23	N/A	N/A	N/A	-1,962.98%	-27.28%	-25.24%	8/13/2026 (Estimated)

Latest ME, MNOV, HRTX, and DWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MNOV MediciNova	-$0.06	N/A	N/A	N/A	$0.08 million	N/A
8/12/2026	Q2 2026	DWTX Dogwood Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
5/14/2026	Q1 2026	DWTX Dogwood Therapeutics	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
5/14/2026	Q1 2026	MNOV MediciNova	-$0.06	-$0.05	+$0.01	-$0.05	$0.19 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
ME 23andMe	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DWTX Dogwood Therapeutics	N/A	5.86	5.86
HRTX Heron Therapeutics	17.51	2.53	1.51
ME 23andMe	N/A	1.05	0.91
MNOV MediciNova	N/A	9.09	9.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DWTX Dogwood Therapeutics	9.05%
HRTX Heron Therapeutics	80.01%
ME 23andMe	36.10%
MNOV MediciNova	9.90%

Insider Ownership

Company	Insider Ownership
DWTX Dogwood Therapeutics	0.30%
HRTX Heron Therapeutics	6.10%
ME 23andMe	26.32%
MNOV MediciNova	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DWTX Dogwood Therapeutics	5	33.63 million	33.53 million	N/A
HRTX Heron Therapeutics	300	189.85 million	177.73 million	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable
MNOV MediciNova	10	49.22 million	42.33 million	Optionable

ME, MNOV, HRTX, and DWTX Headlines

Recent News About These Companies

MediciNova (MNOV) Expected to Release Earnings on Thursday

August 6, 2026 | americanbankingnews.com

MediciNova (MNOV) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts

July 26, 2026 | marketbeat.com

MediciNova, Inc. (NASDAQ:MNOV) Sees Significant Increase in Short Interest

July 16, 2026 | marketbeat.com

MediciNova Achieves Full Enrollment in NIH-Funded SEANOBI-ALS Study of MN-166 (Ibudilast) for ALS

July 15, 2026 | quiverquant.comQ

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

July 15, 2026 | globenewswire.com

MediciNova CEO Provides Shareholder Update

June 30, 2026 | globenewswire.com

MediciNova Shareholders Reject Proposal to Increase Authorized Stock

June 24, 2026 | tipranks.com

MNOV Share News Today

June 21, 2026 | uk.investing.com

MediciNova (MNOV) Stock Forecast & Price Target

June 11, 2026 | investing.com

MediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026 | finanznachrichten.de

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026 | globenewswire.com

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical ...

May 26, 2026 | caledonianrecord.comC

MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes

May 26, 2026 | quiverquant.comQ

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

May 26, 2026 | globenewswire.com

MediciNova Announces New Insights on Brain Metastasis Vulnerability and Potential Therapeutic Strategies from CNIO Study

April 27, 2026 | quiverquant.comQ

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

April 27, 2026 | globenewswire.com

HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation

March 17, 2026 | msn.com

MediciNova to Participate at the 38th Annual ROTH Conference

March 16, 2026 | globenewswire.com

MediciNova: Q4 Earnings Snapshot

February 20, 2026 | wtop.comW

MediciNova (MNOV) price target increased by 28.57% to 9.18

February 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ME, MNOV, HRTX, and DWTX Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

$1.92 +0.09 (+4.62%)

As of 08/12/2026 04:00 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Heron Therapeutics NASDAQ:HRTX

$0.34 +0.02 (+5.28%)

As of 08/12/2026 04:00 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

MediciNova NASDAQ:MNOV

$1.33 +0.01 (+0.76%)

As of 08/12/2026 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ME, MNOV, HRTX, and DWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ME, MNOV, HRTX, and DWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ME, MNOV, HRTX, and DWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ME, MNOV, HRTX, and DWTX Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Heron Therapeutics NASDAQ:HRTX

23andMe NASDAQ:ME

MediciNova NASDAQ:MNOV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ME, MNOV, HRTX, and DWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ME, MNOV, HRTX, and DWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ME, MNOV, HRTX, and DWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ME, MNOV, HRTX, and DWTX Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

Heron Therapeutics NASDAQ:HRTX

23andMe NASDAQ:ME

MediciNova NASDAQ:MNOV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools